FIELD: medicine.
SUBSTANCE: invention refers to pharmaceutical industry and represents the use of a pharmaceutical composition containing 3-[5-amino-4-(3-cyanobenzoyl)pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide, for treating AECOPD in a human patient, wherein three separate therapeutically effective doses of 3-[5-amino-4-(3-cyanobenzoyl) pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide are administered to a patient for a period of not more than ten days with at least one during the day between each batching.
EFFECT: invention provides effective treatment and relief of AECOPD symptoms and absence of acne-like rash in patients.
22 cl, 1 tbl, 4 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOSING REGIMEN FOR TREATING ACUTE EXACERBATIONS OF INFLAMMATORY CONDITIONS | 2016 |
|
RU2709509C1 |
| APPLICATION OF PYRAZOLE DERIVATIVE IN TREATMENT OF ACUTE ATTACKS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2013 |
|
RU2625762C2 |
| METHOD FOR PRODUCING A POLYMORPHIC FORM OF 3-[5-AMINO-4-(3-CYANOBENZOYL)PYRAZOLE-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE | 2017 |
|
RU2792728C2 |
| METHOD FOR PRODUCING POLYMORPH FORM OF 3-[5-AMINO-4-(3-CYANOBENZOYL)PYRAZOLE-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE | 2017 |
|
RU2765719C2 |
| DERIVATIVES OF 5-MEMBER HETEROCYCLES AS KINASE p38 INHIBITORS | 2004 |
|
RU2381219C2 |
| TOSYLATE SALT OF 5-PYRAZOLYL-2-PYRIDONE DERIVATIVE EFFECTIVE IN COPD TREATMENT | 2010 |
|
RU2526038C2 |
| COMBINATION TREATMENT OF CANCER | 2012 |
|
RU2640485C2 |
| SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | 2014 |
|
RU2683793C2 |
| COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF | 2013 |
|
RU2650646C2 |
| TREATMENT OF HYDRADENITIS WITH JAK INHIBITORS | 2020 |
|
RU2805595C1 |
